It hasn’t taken former Agios Pharmaceuticals CEO David Schenkein very long to find a new gig. Schenkein—the Genentech veteran who helped steer Agios (NASDAQ: [[ticker:AGIO]]) to two drug approvals in less than a decade—has been hired by GV, the venture arm of Google’s parent company, Alphabet (NASDAQ: [[ticker:GOOGL]]), Bloomberg first reported. In his new role … Continue reading “GV Taps Ex-Agios CEO Schenkein to Lead Life Science Investments”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Harpoon’s IPO Spears $76M as Prostate Cancer Drug Continues Testing
Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets, raising approximately $76 million in an initial public offering. South San Francisco, CA-based Harpoon offered 5.4 million shares Thursday evening priced at $14 each, which was the midpoint of the range that the company had targeted. Harpoon shares are expected to … Continue reading “Harpoon’s IPO Spears $76M as Prostate Cancer Drug Continues Testing”
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials
Alector, a company taking an immunotherapy approach to Alzheimer’s disease and other brain disorders, has raised approximately $176 million in an initial public offering. The South San Francisco, CA, biotech sold 9.25 million shares Wednesday evening priced at $19 apiece, which was the midpoint of its targeted $18 to $20 per share range. Those shares … Continue reading “Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials”
Chimerix Executive Michelle Berrey Resigns as CEO, Board Member
Michelle Berrey has resigned as CEO of antiviral drugs developer Chimerix (NASDAQ: [[ticker:CMRX]]). She has also stepped down from the Durham, NC, company’s board of directors. Chimerix gave no reason for Berrey’s resignation. Until her successor is found, the company has created a new position, the office of the chief executive officer, that will be … Continue reading “Chimerix Executive Michelle Berrey Resigns as CEO, Board Member”
Frequency Chief Medical Officer Weber Jumps to Decibel Therapeutics
Peter Weber is now chief medical officer of Decibel Therapeutics, a Boston company developing treatments for hearing loss. Before joining Decibel, Weber was the chief medical officer of Frequency Therapeutics, a clinical-stage company based in Woburn, MA, that is also developing hearing loss drugs. Weber is the head of otology/neurotology at Boston University Medical Center, … Continue reading “Frequency Chief Medical Officer Weber Jumps to Decibel Therapeutics”
Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors
In cancer lingo, “cold” tumors are cancers that the immune system doesn’t recognize or respond to, even when immune-stimulating drugs are given. Bolt Biotherapeutics is developing drugs intended to turn cold tumors—the majority of cancers—“hot” so that other immunotherapies can work, and has raised $54 million to support its research. The Redwood City, CA, startup … Continue reading “Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors”
Lauring Leaves Takeda for Chief Medical Officer Post at Kallyope
Brett Lauring is now the chief medical officer of Kallyope. Lauring comes to the New York-based biotech from Takeda Pharmaceutical (NYSE: [[ticker:TAK]]), where he was vice president, translational research and early clinical development. His experience also includes multiple positions at Merck (NYSE: [[ticker:MRK]]). Kallyope, which raised $66 million in financing nearly a year ago, is … Continue reading “Lauring Leaves Takeda for Chief Medical Officer Post at Kallyope”
Sojournix Appoints Ruth Thieroff-Ekerdt Chief Medical Officer
Ruth Thieroff-Ekerdt has been appointed senior vice president and chief medical officer of Sojournix, a Waltham, MA-based women’s health company. She most recently worked at Kaleido Biosciences as its chief medical officer, a position she previously held at Strongbridge Biopharma and Aptalis Pharmaceuticals. Last month, Sojournix closed a $44 million Series C round of funding. … Continue reading “Sojournix Appoints Ruth Thieroff-Ekerdt Chief Medical Officer”
FDA Rejects Alkermes Depression Drug, Asks for More Clinical Data
The FDA has rejected a depression drug from Alkermes, unpersuaded that the company’s experimental treatment actually works. Alkermes said Friday afternoon that the FDA’s letter asked the company for additional clinical data “to provide substantial evidence of effectiveness” for the drug, ALKS 5461. The company, which is based in Dublin, Ireland, and maintains a large … Continue reading “FDA Rejects Alkermes Depression Drug, Asks for More Clinical Data”
Allen Institute Adds Peterson, Hackett to Executive Team
The Allen Institute announced that Todd Peterson has joined as chief scientific officer, a new position at the Seattle bioscience research organization. Before joining the nonprofit institute, Peterson was chief technology officer for La Jolla, CA-based Synthetic Genomics. The institute also hired Lauren Hackett to serve as chief operations officer. She was most recently executive … Continue reading “Allen Institute Adds Peterson, Hackett to Executive Team”
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
Pharmaceutical companies typically raise prescription drug prices at the start of each year and this year was no different. The increases were the latest reminder that, despite President Trump’s fiery campaign rhetoric, the administration had done little to actually lower drug prices. But a new plan aimed at the secretive rebate deals between pharma companies … Continue reading “Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More”
Aleksandra Rizo Departs Celgene for Geron Chief Medical Post
Aleksandra Rizo has been appointed chief medical officer of Geron (NASDAQ: [[ticker:GERN]]). Rizo comes to the Menlo Park, CA, drug developer from Summit, NJ-based Celgene (NASDAQ: [[ticker:CELG]]), where she was executive director, strategy and clinical lead. Geron also says it will open a New Jersey office to support its lead drug candidate, imetelstat. The Geron … Continue reading “Aleksandra Rizo Departs Celgene for Geron Chief Medical Post”
Sunovion’s FDA Rejection Gives Acorda Parkinson’s Drug Breathing Room
The FDA has rejected a Sunovion Pharmaceuticals drug for Parkinson’s disease, delaying the company in its bid to compete with Acorda Therapeutics, which has a similar product that was recently approved for the market. Sunovion said late Wednesday that the FDA asked for more information to support the application for its drug, APL-130277. But the … Continue reading “Sunovion’s FDA Rejection Gives Acorda Parkinson’s Drug Breathing Room”
Genentech’s Mobasher Joins Corvus as Chief Medical Officer
Corvus Pharmaceuticals (NASDAQ: [[ticker:CRVS]]) has appointed Mehrdad Mobasher to serve as vice president and chief medical officer. Mobasher comes to Burlingame, CA-based Corvus after eight years at Genentech, where he was most recently group medical director. Lead Corvus drug candidate CPI-444 is in early-stage clinical testing in various solid tumors. Corvus is developing that drug … Continue reading “Genentech’s Mobasher Joins Corvus as Chief Medical Officer”
Eisai Exec Voliotis Joins CureVac as Chief Development Officer
Dimitris Voliotis has been appointed chief development officer of German biotech CureVac. Voliotis, who was most recently senior vice president and head of global clinical development for Eisai, will work from CureVac’s Boston office. CureVac is developing messenger RNA drugs intended to deliver the genetic instructions that enable a patient’s cells to produce therapeutic proteins.
Aduro Biotech Slashes Staff 37%, Turns Focus to Lead Cancer Drugs
Aduro Biotech is laying off more than a third of its workforce in a restructuring intended to keep its focus on its cancer drugs now in clinical development. The corporate shakeup will cut the headcount of Aduro (NASDAQ: [[ticker:ADRO]]) by 37 percent, the company announced Wednesday. At the end of the third quarter of last … Continue reading “Aduro Biotech Slashes Staff 37%, Turns Focus to Lead Cancer Drugs”
Gilead, Gates Foundation Join Lyndra’s $55M Funding for Phase 2 Tests
Lyndra Therapeutics, a startup whose technology turns daily pills into extended-release formulations intended to last a week or longer, has raised $55 million to advance several of its drugs into mid-stage studies. The Series B round of funding was led by Polaris Partners, the firm that also led Lyndra’s Series A financing nearly two years … Continue reading “Gilead, Gates Foundation Join Lyndra’s $55M Funding for Phase 2 Tests”
Former Sanofi Exec Koenig Joins Portola as Chief Commercial Officer
Portola Pharmaceuticals (NASDAQ: [[ticker:PTLA]]) has named Sheldon Koenig executive vice president and chief commercial officer. He comes to South San Francisco, CA-based Portola from Sanofi (NYSE: [[ticker:SNY]]), where he was head of the company’s cardiovascular franchise. His experience also includes leadership positions at Merck (NYSE: [[ticker:MRK]]). Portola received FDA approval last year for andexanet alfa … Continue reading “Former Sanofi Exec Koenig Joins Portola as Chief Commercial Officer”
Indalo Therapeutics Names Robert Jacks President & CEO
Indalo Therapeutics has appointed Robert Jacks to serve as president and CEO. Jacks was most recently president and chief financial officer of Symbiomix Therapeutics, which was acquired by Lupin in 2017. Indalo was formed by the 2016 merger of Antegrin Therapeutics and Cascadia Therapeutics. The Cambridge, MA-based company’s lead drug candidate, IDL-2965, is expected to … Continue reading “Indalo Therapeutics Names Robert Jacks President & CEO”
Alexander Hardy Returns to Genentech as CEO
Roche’s Genentech unit has appointed Alexander Hardy to serve as CEO. He initially joined South San Francisco, CA-based Genentech in 2005 and worked there in several senior management roles until 2014 when he became head of Asia Pacific for Roche’s pharmaceuticals division. Hardy is currently Roche’s head of global product strategy. At Genentech, he will … Continue reading “Alexander Hardy Returns to Genentech as CEO”
Vertex Pharmaceuticals Exec Ian Smith Fired for “Personal Behavior”
Ian Smith, chief operating officer and interim chief financial officer of Vertex Pharmaceuticals, has been terminated from his positions following an investigation, the company announced Wednesday. Boston-based Vertex (NASDAQ: [[ticker:VRTX]]) said the personnel decision was made due to “personal behavior that violated Vertex’s Code of Conduct and values.” The company did not specify what prompted … Continue reading “Vertex Pharmaceuticals Exec Ian Smith Fired for “Personal Behavior””
Eli Lilly’s Oxtoby Jumps to Aimmune for Chief Commercial Officer Post
Aimmune Therapeutics (NASDAQ: [[ticker:AIMT]]) has appointed Andrew Oxtoby to serve as its chief commercial officer. Oxtoby comes to Brisbane, CA-based Aimmune after 16 years at Eli Lilly (NYSE: [[ticker:LLY]]), most recently as vice president of U.S. diabetes connected care and insulins. Aimmune is awaiting an FDA decision on its experimental peanut-allergy treatment, AR101.
BridgeBio Pharma Hauls in $299M for Genetic Disease Drugs R&D
Biotech startup creator BridgeBio Pharma has raised $299.2 million to support its work developing new drugs to treat rare, genetic diseases. Palo Alto, CA-based BridgeBio searches for promising drug research at universities, academic medical centers, and drug companies. After acquiring rights to a compound, BridgeBio forms a subsidiary company to develop it. Operating under a … Continue reading “BridgeBio Pharma Hauls in $299M for Genetic Disease Drugs R&D”
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
Editas Medicine has the regulatory blessing to test its experimental gene-editing therapy in humans, and a $25 million check from its partner, Allergan, for hitting that milestone. But Editas will conduct the clinical trial without Katrine Bosley, the CRISPR biotech’s top executive for nearly the last five years. Bosley is leaving her post as president … Continue reading “Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial”
Insmed’s Paul Streck Joins Alder Bio as Chief Medical Officer
Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]) has appointed Paul Streck to serve as chief medical officer, a post he held at his former company, Insmed (NASDAQ: [[ticker:INSM]]). His experience also includes roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]), Shire, and Amgen (NASDAQ: [[ticker:AMGN]]). Alder’s lead drug, eptinezumab, was developed to prevent migraine pain. The Bothell, WA-based company has said … Continue reading “Insmed’s Paul Streck Joins Alder Bio as Chief Medical Officer”
FDA Places Clinical Hold on Translate Bio’s mRNA Drug Study
Translate Bio’s plans to test a messenger RNA (mRNA) drug in patients who have a rare metabolic disorder have been halted by the FDA. Lexington, MA-based Translate Bio (NASDAQ: [[ticker:TBIO]]) said Tuesday that the regulator verbally notified it of “additional clinical and nonclinical questions” about the company’s submission. Until those questions are resolved, the FDA … Continue reading “FDA Places Clinical Hold on Translate Bio’s mRNA Drug Study”
Failed Clinical Trial Puts Eli Lilly Cancer Drug in Limbo
An Eli Lilly drug on the market for a rare form of cancer is now in limbo, after it failed a trial needed to retain the FDA approval the treatment, known as olaratumab (Lartruvo), won two years ago. Lilly (NYSE: [[ticker:LLY]]) said Friday that patients in a Phase 3 study with soft tissue sarcoma who … Continue reading “Failed Clinical Trial Puts Eli Lilly Cancer Drug in Limbo”
Terns Pharma Names Ex-Gilead Exec Erin Quirk Chief Medical Officer
Terns Pharmaceuticals has appointed Erin Quirk to serve as its chief medical officer. Quirk most recently worked at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where she was vice president, clinical research. Terns, which has operations in San Mateo, CA, and Shanghai, China, raised $30 million in financing last year to support development of drugs for the fatty … Continue reading “Terns Pharma Names Ex-Gilead Exec Erin Quirk Chief Medical Officer”
Paul Sekhri Joins eGenesis as President & CEO
Biotech company eGenesis has appointed Paul Sekhri to serve as president and CEO, a position he held at his previous company, Lycera. Sekhri’s experience also includes posts at Teva Pharmaceutical Industries (NYSE: [[ticker:TEVA]]), Cerimon Pharmaceuticals, and Ariad Pharmaceuticals. Sekhri succeeds eGenesis interim CEO Julie Sunderland, who will join the Cambridge, MA, company’s board of directors. … Continue reading “Paul Sekhri Joins eGenesis as President & CEO”
FDA Panel Backs Amgen Bone Drug, Says Benefits Outweigh Heart Risks
[Updated 1/17/19, 8:50 a.m. See below.] An experimental Amgen osteoporosis drug that had sparked concern about cardiovascular side effects has won the backing of an FDA advisory panel. A total of 15 panelists on Thursday voted that the benefits of the drug, romosozumab (Evenity), outweigh its risks, and are enough to support its approval. But … Continue reading “FDA Panel Backs Amgen Bone Drug, Says Benefits Outweigh Heart Risks”
Five Prime’s Shakeup Cuts Staff 20%, Keeps Focus on Clinical Programs
Five Prime Therapeutics is cutting its headcount by 20 percent, part of a cash-saving effort the company is making to focus on the cancer drugs it has already advanced into clinical trials. South San Francisco, CA-based Five Prime (NASDAQ: [[ticker:FPRX]]) said Tuesday that the corporate restructuring will reduce operating expenses by $10 million in 2019 … Continue reading “Five Prime’s Shakeup Cuts Staff 20%, Keeps Focus on Clinical Programs”
Roche Veteran Khwaja Named Voyager Therapeutics Chief Medical Officer
Omar Khwaja has been appointed chief medical officer of Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]). Khwaja comes to the Cambridge, MA-based gene therapy developer from Roche, where he was most recently global head of neuroscience translational medicine and global head of rare diseases. Voyager’s lead drug, VY-AADC, is in mid-stage studies testing it in advanced Parkinson’s disease.
Seres Promotes Shaff to CEO, Pomerantz Continues as Chairman
Eric Shaff, chief operating and financial officer of Seres Therapeutics (NASDAQ: [[ticker:MCRB]]), has been promoted to president and CEO. Shaff is also joining the board of directors of the Cambridge, MA, microbiome drugs developer. Shaff joined Seres as chief financial officer in 2014 and last year took on the additional role of chief operating officer. … Continue reading “Seres Promotes Shaff to CEO, Pomerantz Continues as Chairman”
Kaleido Bio and Cirius Join an IPO Queue Stalled by Federal Shutdown
The partial government shutdown may have diminished staffing at the SEC, but it hasn’t dimmed the hopes of biotech firms hoping to go public. On Friday, Kaleido Biosciences and Cirius Therapeutics both filed paperwork for their respective initial public offerings with the securities regulator. While it’s operating with “very limited staff” due to the shutdown, … Continue reading “Kaleido Bio and Cirius Join an IPO Queue Stalled by Federal Shutdown”
GeneCentric Promotes Michael Milburn to CEO & President
Four months after joining GeneCentric as chief scientific officer, Michael Milburn has been promoted to CEO and president of the Durham, NC, company. He succeeds founder, CEO, and president Myla Lai-Goldman, who is taking on the newly created role of executive chairperson of the board of directors. GeneCentric develops tests that match a cancer drug … Continue reading “GeneCentric Promotes Michael Milburn to CEO & President”
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology. Loxo (NASDAQ: [[ticker:LOXO]]) has made a name for itself by becoming one of just two companies ever to earn an … Continue reading “Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More”
Former Roche Exec Pearl Huang Joins Cygnal Therapeutics as CEO
Cygnal Therapeutics has appointed Pearl Huang to serve as its CEO. Huang most recently worked at Roche, where she was senior vice president and global head of therapeutic modalities. Her experience also includes executive roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]), Merck (NYSE: [[ticker:MRK]]), and BeiGene (NASDAQ: [[ticker:BGNE]]). Cambridge, MA-based Cygnal developed within the labs of venture … Continue reading “Former Roche Exec Pearl Huang Joins Cygnal Therapeutics as CEO”
Black Diamond Gets $85M for Cancer Drugs R&D and New Cambridge HQ
When Black Diamond Therapeutics emerged from stealth mode last month with $20 million in backing and a handful of preclinical cancer drugs, the company signaled that another financing was in the works for 2019. That day is here. Black Diamond announced late Wednesday that it has closed $85 million in Series B financing, which the … Continue reading “Black Diamond Gets $85M for Cancer Drugs R&D and New Cambridge HQ”
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
Beta Bionics, a startup developing a medical device that monitors and manages blood sugar levels in diabetes patients, has closed $63 million to back late-stage clinical tests of its AI-powered technology. The cash tops off a Series B round of funding announced last year. The Boston company, which counts diabetes drug giants Eli Lilly (NYSE: … Continue reading “Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests”
Foundation Medicine Appoints Roche’s Cindy Perettie CEO
Foundation Medicine has appointed Cindy Perettie to serve as its CEO. Perettie comes to Cambridge, MA-based Foundation from Roche, where she was a senior vice president in global oncology product strategy for the company’s oncology unit. Perettie will start at Foundation on Feb. 4 succeeding Troy Cox, who has been CEO for the past two … Continue reading “Foundation Medicine Appoints Roche’s Cindy Perettie CEO”
Barlow Departs Parkinson’s Institute for CMO Post at E-Scape Bio
Carrolee Barlow has joined E-Scape Bio as chief medical officer. Barlow comes to the San Francisco biotech from the Parkinson’s Institute and Clinical Center, where she was CEO. Her experience also includes executive posts at Amicus Therapeutics (NASDAQ: [[ticker:FOLD]]) and BrainCells, a company she co-founded to develop treatments for neurological and psychiatric disease. E-Scape, which … Continue reading “Barlow Departs Parkinson’s Institute for CMO Post at E-Scape Bio”
Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs
Alector, a biotech company focusing on the immune system to treat degenerative brain disorders such as Alzheimer’s disease, has filed to go public to fund human tests of its experimental therapies. South San Francisco, CA-based Alector set a preliminary $150 million target for its IPO. The company has applied for a listing on the Nasdaq … Continue reading “Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs”
Bio-JPM Roundup: Lilly Buys Loxo, Sage’s Stock Soars, ALS Cash & More
The flow of biotech news is particularly heavy today, and for good reason. The annual J.P. Morgan Healthcare Conference, one of the biggest gatherings for the biopharmaceutical industry, kicked off today in San Francisco, and many companies, whether they’re speaking at the event or not, use this time to get their news out. Xconomy is … Continue reading “Bio-JPM Roundup: Lilly Buys Loxo, Sage’s Stock Soars, ALS Cash & More”
Eli Lilly Makes an $8B Cancer Genetics Bet with Loxo Acquisition
[Updated 1/7/19, 11 a.m. ET. See below.] Eli Lilly is set to acquire Loxo Oncology for approximately $8 billion—a deal that brings to the Indianapolis pharmaceutical giant a class of drugs that treat cancers with particular genetic signatures. Under the agreement announced Monday, Lilly (NYSE: [[ticker:LLY]]) will pay $235 cash per share of Loxo (NASDAQ: … Continue reading “Eli Lilly Makes an $8B Cancer Genetics Bet with Loxo Acquisition”
Allena Promotes Brenner to CEO, Margolin Becomes Board Chair
Louis Brenner, president and chief operating officer at Allena Pharmaceuticals (NASDAQ: [[ticker:ALNA]]), will become CEO starting Feb. 1. He will also join the Newton, MA, company’s board of directors. Allena co-founder and current CEO Alexey Margolin will shift to a new role as chairman of the board. Launched in 2011, Allena went on to raise … Continue reading “Allena Promotes Brenner to CEO, Margolin Becomes Board Chair”
Ultragenyx Exec Mansbach Joins 89bio as Chief Medical Officer
Hank Mansbach has been appointed chief medical officer of 89bio. Mansbach comes to the biotech startup from Ultragenyx (NASDAQ: [[ticker:RARE]]), where he was head of metabolic and neurology global clinical development. 89bio, which splits its operations between San Francisco and Herzliya, Israel, raised $60 million in financing last October to support its development of a … Continue reading “Ultragenyx Exec Mansbach Joins 89bio as Chief Medical Officer”
Genentech, Adaptive Bio Join Forces on Personalized Cancer Drugs R&D
Genentech is paying Adaptive Biotechnologies $300 million up front in a new partnership focused on developing cancer immunotherapies personalized to individual patients. Seattle-based Adaptive has technology that can analyze the immune system to find targets for cell therapies. Adaptive says that its screening technology enables it to discover T-cell receptors (TCRs) that can recognize and … Continue reading “Genentech, Adaptive Bio Join Forces on Personalized Cancer Drugs R&D”
Liz Barrett Leaves Novartis to Become UroGen President and CEO
UroGen Pharma (NASDAQ: [[ticker:URGN]]) has appointed Liz Barrett to serve as its president and CEO. Barrett is also joining the board of directors of the company, which was founded in Israel and recently moved its headquarters to New York. UroGen, a clinical-stage company developing treatments for urologic cancers, says Barrett will be based in New … Continue reading “Liz Barrett Leaves Novartis to Become UroGen President and CEO”
SQZ Biotech Appoints Oliver Rosen Chief Medical Officer
Oliver Rosen has joined SQZ Biotechnologies as the Watertown, MA, company’s chief medical officer. Rosen was most recently chief medical officer of Deciphera Pharmaceuticals (NASDAQ: [[ticker:DCPH]]) in Waltham, MA. His experience also includes senior roles at Millenium Pharmaceuticals and Genentech. SQZ is developing cell therapies based on its technology that inserts therapeutic proteins into a … Continue reading “SQZ Biotech Appoints Oliver Rosen Chief Medical Officer”
Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance
A cancer immunotherapy teed up for clinical trials by Tizona Therapeutics is now the centerpiece of a new partnership with AbbVie, which is paying the startup $105 million up front. In addition to the cash paid to South San Francisco, CA-based Tizona, AbbVie (NYSE: [[ticker:ABBV]]) said Thursday that it has made an equity investment in … Continue reading “Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance”